There are only a small number of reports on the outcome of scalp tumors treated with Mohs micrographic surgery (MMS).
The objective was to present a large series of patients with scalp tumors treated with MMS in Australia between 1993 and 2002.
This prospective, multicenter study included all patients with scalp tumors who were monitored by the Skin and Cancer Foundation Australia. The variables analyzed were patient demographics, reason for referral, preoperative tumor size and postoperative defect size, recurrences before MMS, histologic subtypes, perineural invasion, and 5-year recurrence.
The study included 316 patients (68% men) with a mean age of 65±15 years. The most common tumors were basal cell carcinoma (BCC), 57.9%; squamous cell carcinoma (SCC), 35.8%; Bowen's disease (BD), 4.1%; and atypical fibroxanthoma (AFX), 1.6%. Recurrent tumors comprised 37% of cases. The recurrence rate for 70 BCC patients who completed the 5-year follow-up was 5.7%, and for 31 SCC cases it was 3.2%. No cases of recurrence were noted in the patients with BD and AFX.
BCC was the most common scalp tumor managed by MMS. The low 5-year recurrence rate emphasizes the importance of margin controlled excision of scalp tumors.
*Oculoplastic & Orbital Division
†Department of Dermatology, Royal Adelaide Hospital, University of Adelaide, Adelaide
‡Wakefield Clinic, Adelaide
§Skin & Cancer Foundation Australia, Sydney, New South Wales
∥Departments of Surgery & Medicine, University of Adelaide, Adelaide, South Australia
Address correspondence and reprint requests to: Dr. Igal Leibovitch, Oculoplastic & Orbital Division, Royal Adelaide Hospital, Adelaide, South Australia, or e-mail: email@example.com.